menu
    • menu
    [{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"University of Colorado","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ University of Colorado","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ University of Colorado"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"Binimetinib","moa":"Class I HDAC","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"OnKure Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Surveyor Capital","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Series C Financing","leadProduct":"OKI-219","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Surveyor Capital","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Surveyor Capital"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Not Applicable","leadProduct":"OKI-219","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"5","companyTruncated":"OnKure Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ OnKure Therapeutics"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ OnKure Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"OnKure Therapeutics \/ OnKure Therapeutics"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Reneo Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Merger","leadProduct":"Fulvestrant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OnKure Therapeutics","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ OnKure Therapeutics","highestDevelopmentStatusID":"14","companyTruncated":"OnKure Therapeutics \/ OnKure Therapeutics"},{"orgOrder":0,"company":"OnKure Therapeutics","sponsor":"Leerink Partners","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Private Placement","leadProduct":"Fulvestrant","moa":"","graph1":"Technology","graph2":"Phase I\/II","graph3":"OnKure Therapeutics","amount2":0.070000000000000007,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Technology","amount2New":0.94999999999999996,"dosageForm":"","sponsorNew":"OnKure Therapeutics \/ Leerink Partners","highestDevelopmentStatusID":"14","companyTruncated":"OnKure Therapeutics \/ Leerink Partners"}]

    Find Clinical Drug Pipeline Developments & Deals by OnKure Therapeutics

    Menu

    OnKure Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            OnKure Closes Merger with Reneo Pharmaceuticals, Raises $65 Million

                            Details : The combined company will focus on OnKure’s candidates targeting oncogenic mutations in PI3K alpha, including OKI-219, which is in Phase 1 for the treatment of solid tumors.

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Leerink Partners

                            Deal Size : $65.0 million

                            Deal Type : Private Placement

                            DEALS_DEV arrow-down

                            OnKure Closes Merger with Reneo Pharmaceuticals, Raises $65 Million

                            Details : The combined company will focus on OnKure’s candidates targeting oncogenic mutations in PI3K alpha, including OKI-219, which is in Phase 1 for the treatment of solid tumors.

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            October 04, 2024

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Leerink Partners

                            Deal Size : $65.0 million

                            Deal Type : Private Placement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Reneo Pharmaceuticals and OnKure Announce Proposed Merger

                            Details : The combined company will focus on advancing OnKure’s pipeline candidates targeting oncogenic mutations in PI3Kα, including its lead program OKI-219, currently in Phase 1 for solid tumors.

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 13, 2024

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            DEALS_DEV arrow-down

                            Reneo Pharmaceuticals and OnKure Announce Proposed Merger

                            Details : The combined company will advance OnKure’s pipeline targeting oncogenic mutations in PI3K alpha, including its lead program OKI-219, which is in Phase 1 trial for the treatment of solid tumors.

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 13, 2024

                            Lead Product(s) : OKI-219,Fulvestrant

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Reneo Pharmaceuticals

                            Deal Size : Undisclosed

                            Deal Type : Merger

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OnKure Announces IND Clearance by FDA Enabling Phase 1 Initiation for OKI-219

                            Details : OKI-219 is a potential best-in-class, orally bioavailable, highly selective inhibitor of PI3Kα H1047R, which is being evaluated for the treatment of HER2+/ PI3Kα H1047R breast cancer.

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            January 04, 2024

                            Lead Product(s) : OKI-219

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-219

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Surveyor Capital

                            Deal Size : $54.0 million

                            Deal Type : Series C Financing

                            DEALS_DEV arrow-down

                            OnKure Therapeutics Announces $54 Million Series C Financing

                            Details : The proceeds will be used to support the continued development of OnKure’s differentiated pipeline of next generation precision medicines, including the advancement of its lead discovery program OKI-219, a selective PI3K alpha H1047R inhibitor, into th...

                            Brand Name : OKI-219

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            May 23, 2023

                            Lead Product(s) : OKI-219

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Surveyor Capital

                            Deal Size : $54.0 million

                            Deal Type : Series C Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OnKure Therapeutics Announces First Patient Dosed in the Phase 1b/2 Nautilus Trial of OKI-179 in Combination w...

                            Details : OKI-179 is a novel, oral Class I histone deacetylase (HDAC) inhibitor for the potential treatment of a wide range of solid and hematological malignancies.

                            Brand Name : OKI-179

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 02, 2022

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OnKure Therapeutics Announces Promising Preclinical Data on OKI-179 in RAS-Mutated Tumor Models Presented in a...

                            Details : OKI-179 combined with binimetinib in NRAS-mutated melanoma or combined with binimetinib + encorafenib in BRAF-mutated colorectal xenografts showed significantly increased regressions compared to either single agent following two weeks of dosing.

                            Brand Name : OKI-179

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            April 08, 2022

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed

                            OnKure Therapeutics

                            U.S.A arrow
                            CPhI India 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : University of Colorado

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            OnKure Therapeutics to Present Late-Breaking Preclinical Data on OKI-179 at the AACR Annual Meeting 2022

                            Details : OKI-179, a novel oral Class I histone deacetylase inhibitor for treatment of wide range of solid and hematological malignancies, increases tumor regressions when combined with the MEK inhibitor binimetinib in models of NRAS melanoma.

                            Brand Name : OKI-179

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            March 08, 2022

                            Lead Product(s) : OKI-179,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : University of Colorado

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth